These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 11122504)

  • 1. Validation, calibration, revision and combination of prognostic survival models.
    van Houwelingen HC
    Stat Med; 2000 Dec; 19(24):3401-15. PubMed ID: 11122504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of treatment on the prognostic value of S-phase fraction in non-Hodgkin's lymphoma.
    Joensuu H; Ristamäki R; Söderström KO; Jalkanen S
    J Clin Oncol; 1994 Oct; 12(10):2167-75. PubMed ID: 7931487
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-dependent effect of non-Hodgkin's lymphoma grade on disease-free survival of relapsed/refractory patients treated with high-dose chemotherapy plus autotransplantation.
    Fu P; van Heeckeren WJ; Wadhwa PD; Bajor DJ; Creger RJ; Xu Z; Cooper BW; Laughlin MJ; Gerson SL; Koç ON; Lazarus HM
    Contemp Clin Trials; 2008 Mar; 29(2):157-64. PubMed ID: 17707140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advanced diffuse non-Hodgkin's lymphoma. Analysis of prognostic factors by the international index and by lactic dehydrogenase in an intergroup study.
    Gordon LI; Andersen J; Colgan J; Glick J; Resnick GD; O'Connell M; Cassileth PA
    Cancer; 1995 Feb; 75(3):865-73. PubMed ID: 7530168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. External validation of a Cox prognostic model: principles and methods.
    Royston P; Altman DG
    BMC Med Res Methodol; 2013 Mar; 13():33. PubMed ID: 23496923
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Estimation of regression parameters and the hazard function in transformed linear survival models.
    Gray RJ
    Biometrics; 2000 Jun; 56(2):571-6. PubMed ID: 10877318
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Survival analysis with time-varying regression effects using a tree-based approach.
    Xu R; Adak S
    Biometrics; 2002 Jun; 58(2):305-15. PubMed ID: 12071403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors for treatment outcome in autotransplantation of intermediate-grade and high-grade non-Hodgkin's lymphoma with cyclophosphamide, carmustine, and etoposide.
    Wheeler C; Strawderman M; Ayash L; Churchill WH; Bierer BE; Elias A; Gilliland DG; Antman K; Guinan EC; Eder JP
    J Clin Oncol; 1993 Jun; 11(6):1085-91. PubMed ID: 8099120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A prognostic index for systemic AIDS-related non-Hodgkin lymphoma treated in the era of highly active antiretroviral therapy.
    Bower M; Gazzard B; Mandalia S; Newsom-Davis T; Thirlwell C; Dhillon T; Young AM; Powles T; Gaya A; Nelson M; Stebbing J
    Ann Intern Med; 2005 Aug; 143(4):265-73. PubMed ID: 16103470
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Non-Hodgkin's lymphomas. II. Analysis of the prognostic factors in a series of 307 patients].
    García Zueco JC; Delgado MP; Giraldo MP; Perella M; Rubio-Félix D; Giralt M
    Sangre (Barc); 1992 Oct; 37(5):337-44. PubMed ID: 1293772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intestinal non-Hodgkin's lymphoma: a multicenter prospective clinical study from the German Study Group on Intestinal non-Hodgkin's Lymphoma.
    Daum S; Ullrich R; Heise W; Dederke B; Foss HD; Stein H; Thiel E; Zeitz M; Riecken EO
    J Clin Oncol; 2003 Jul; 21(14):2740-6. PubMed ID: 12860953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-Hodgkin's lymphomas: characteristics of long-term survivors following conservative treatment.
    Straus DJ; Gaynor JJ; Leiberman PH; Filippa DA; Koziner B; Clarkson BD
    Am J Med; 1987 Feb; 82(2):247-56. PubMed ID: 3812517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor bulk as a prognostic factor for the management of localized aggressive non-Hodgkin's lymphoma: a survey of the Japan Lymphoma Radiation Therapy Group.
    Oguchi M; Ikeda H; Isobe K; Hirota S; Hasegawa M; Nakamura K; Sasai K; Hayabuchi N
    Int J Radiat Oncol Biol Phys; 2000 Aug; 48(1):161-8. PubMed ID: 10924986
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Primary cerebral non-Hodgkin's lymphomas. The results of radiotherapy].
    Hetzel-Sesterheim M; Schnabel K; Nestle U; Hamann G; Berberich W
    Strahlenther Onkol; 1996 Apr; 172(4):198-204. PubMed ID: 8623082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Statistical analysis of localized non-Hodgkin's lymphomas of the head and neck--multivariate analysis of prognostic factors and evaluation of therapeutic modalities].
    Tomita T; Fujii M; Imanishi Y; Kanke M; Kanzaki J; Ohno Y; Tokumaru Y; Inuyama Y
    Nihon Jibiinkoka Gakkai Kaiho; 1999 Jun; 102(6):809-17. PubMed ID: 10429435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Risk-adjusted prognostic models for Hodgkin's disease (HD) and grade II non-Hodgkin's lymphoma (NHL II): validation on 6728 British National Lymphoma Investigation patients.
    Low SE; Horsman JM; Walters SJ; Hancock H; Smith P; Linch D; Hancock BW
    Br J Haematol; 2003 Jan; 120(2):277-80. PubMed ID: 12542487
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent socioeconomic inequalities in cancer survival in the United States: 1973-2007 surveillance, epidemiology and end results (SEER) data for breast cancer and non-Hodgkin's lymphoma.
    Kato I; Booza J; Quarshie WO; Schwartz K
    J Registry Manag; 2012; 39(4):158-66. PubMed ID: 23493021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of two different ProMACE-CytaBOM derived regimens in advanced aggressive non-Hodgkin's lymphoma. Final report of a multicenter trial conducted by GISL.
    Federico M; Clò V; Brugiatelli M; Carotenuto M; Gobbi PG; Vallisa D; Lombardo M; Avanzini P; Di Renzo N; Dini D; Baldini L; Silingardi V
    Haematologica; 1998 Sep; 83(9):800-11. PubMed ID: 9825577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial.
    Stiff PJ; Dahlberg S; Forman SJ; McCall AR; Horning SJ; Nademanee AP; Blume KG; LeBlanc M; Fisher RI
    J Clin Oncol; 1998 Jan; 16(1):48-55. PubMed ID: 9440722
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extranodal non-Hodgkin's lymphomas--a retrospective review of clinico-pathologic features and outcomes in comparison with nodal non-Hodgkin's lymphomas.
    Lal A; Bhurgri Y; Vaziri I; Rizvi NB; Sadaf A; Sartajuddin S; Islam M; Kumar P; Adil S; Kakepoto GN; Masood N; Khurshed M; Alidina A
    Asian Pac J Cancer Prev; 2008; 9(3):453-8. PubMed ID: 19004134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.